For the 8 - and 28-week assignments , 10-year cumulative incidences of locoregional progression were 6 % ( 95 % CI , 4.3 % to 8.0 % ) and 4 % ( 95 % CI , 2.5 % to 5.7 % ; HR , 0.65 ; P = .07 ) , respectively ; 10-year distant metastasis cumulative incidences were 6 % ( 95 % CI , 4.0 % to 7.7 % ) and 6 % ( 95 % CI , 4.0 % to 7.6 % ; HR , 1.07 ; P = .80 ) , respectively ; and 10-year prostate-specific antigen-based recurrence cumulative incidences were 27 % ( 95 % CI , 23.1 % to 29.8 % ) and 27 % ( 95 % CI , 23.4 % to 30.3 % ; HR , 0.97 ; P = .77 ) , respectively .